Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-Covid-19 Vaccine Protection in Immunocompromised Children (1 to 15 Years Old) With Acute Leukemia and Their Siblings (≥12 Years Old). Phase I-II Trial Evaluating Post-vaccine Safety and Humoral and Cellular Immunogenicity.

NCT04969601 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT04969601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04969601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-Covid-19 Vaccine Protection in Immunocompromised Children (1 to 15 Years Old) With Acute Leukemia and Their Siblings (≥12 Years Old). Phase I-II Trial Evaluating Post-vaccine Safety and Humoral and Cellular Immunogenicity.
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 1/2
Overall status
Completed
Start date
September 29, 2021
Completion date
March 1, 2024
Enrollment
76 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia